Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine, Docetaxel, and Pazopanib in Neoadjuvant Soft Tissue Sarcoma
NCT01418001Phase 2Terminated
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 2011
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pazopanib in soft tissue sarcoma (STS), sponsored by Memorial Sloan Kettering Cancer Center. Started Aug 2011; status: terminated.
02
Drugs
pazopanib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT01418001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01418001.